Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Valiant Laboratories reported strong revenue growth with standalone revenue rising 62.8% year-on-year to Rs 21,704.25 Lakhs, while consolidated revenue grew 78% to Rs 23,746.75 Lakhs. Standalone operations turned profitable with net profit of Rs 554.82 Lakhs compared to a loss of Rs 215.02 Lakhs in the previous year. However, consolidated net loss widened to Rs 326.79 Lakhs due to subsidiary losses and significantly higher depreciation (Rs 603.98 Lakhs vs Rs 209.26 Lakhs). The statutory auditor issued an un-modified (clean) opinion on both standalone and consolidated results. Operating cash flow remained negative for both standalone (Rs -1,380.64 Lakhs) and consolidated (Rs -1,043.24 Lakhs), indicating cash consumption despite profitability on standalone basis.
The clean audit opinion and strong standalone profitability are positives for investors. However, the continued consolidated losses, negative operating cash flows, and margin compression may raise concerns about the company's cash conversion and subsidiary performance. The significant revenue growth is a bright spot.